Evaluation of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF) - WISPer Trial
Summary
This study is open to adults aged 40 and older who have idiopathic pulmonary fibrosis (IPF). The goal is to determine if a medicine called MTX-463 can benefit people with IPF.
The study involves 8 visits over a period of up to 32 weeks. Participants will be randomly assigned to receive either the study drug (MTX-463) or placebo through intravenous (IV) infusion. The placebo will look like MTX-463 but will contain no active medicine. There will be a 4 week screening period, a 24 week treatment period, and a 4 week safety follow-up period. Participants will receive 6 infusions throughout the treatment period, one infusion every 4 weeks.
At each visit, the study team will perform regular lung function tests to assess your breathing. These tests will be used to compare results between those taking MTX-463 and the placebo. The study will also monitor your overall health and document any side effects.
Eligibility
Eligible ages: 40 to 100
Inclusion criteria:
You may be eligible to participate if you:
1. Are 40 years old or older at the time of signed informed consent
2. Have a diagnosis of Idiopathic Pulmonary Fibrosis (IPF)
3. Are on stable treatment with nintedanib or pirfenidone for at least 90 days OR not on treatment with nintedanib or pirfenidone for at least 30 days
Exclusion criteria:
You may not be eligible to participate if you:
1. Are under the age of 40 years old
2. Have an acute exacerbation of Idiopathic Pulmonary Fibrosis (IPF) within 6 months prior to Screening
3. Are a current smoker/vaper
Participate
Fill out the following form if you want to participate in this research
UCalgary Notice of Collection
The University of Calgary (UCalgary) respects your privacy and is
committed to ensuring the privacy of all students, staff, and community members. Your personal information is being
collected under the authority of section 4(c) of the Protection of Privacy Act (POPA). It will be collected, used
and disclosed for the purposes outlined in UCalgary’s
Notice of
Collection, Use and Disclosure of Personal Information and managed in accordance with UCalgary’s
Privacy
Management Program.
Your personal information may be input into automated systems to generate content or make decisions,
recommendations, or predictions. If you have questions regarding this notice or UCalgary’s collection,
use, or disclosure of your personal information, please contact
accessandprivacy@ucalgary.ca.
Additional information
Contact information
If you are interested in participating in this study, contact the study coordinator, Madison Kong, at 403-210-7827.
Principal investigator:
Amanda Grant-Orser
Clinical trial:
Yes
REB-ID:
REB25-1369